Jefferies raises Nvidia stock price target to $205 on strong demand
James William Rogers (NYSE:ROG), the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), has sold a significant amount of company stock, according to a recent SEC filing. The sale comes as TEM shares have declined 14% over the past week, though they remain up 127% year-to-date according to InvestingPro data. On February 18, 2025, Rogers disposed of Class A Common Stock valued at approximately $2,616,307. The shares were sold at prices ranging from $79.62 to $90.61.
In a separate transaction on February 19, 2025, Rogers sold additional shares to cover statutory tax withholding obligations related to the vesting of restricted stock units. This sale, mandated by the company’s equity incentive plans, totaled $126,086, with shares sold at prices between $81.83 and $82.36. The $14.08 billion market cap company maintains strong liquidity, with a current ratio of 2.69.
These transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set a schedule for trading company stock to avoid potential conflicts of interest. Following these transactions, Rogers continues to hold a substantial number of shares in Tempus AI. InvestingPro analysis suggests the stock is currently overvalued, with 11 additional key insights available to subscribers.
In other recent news, Tempus AI Inc. has made significant strides with the completion of its acquisition of Ambry Genetics. This strategic move brings a profitable germline testing laboratory with over $300 million in revenue under Tempus AI’s umbrella, positioning the company for expanded product offerings and new market entries. TD Cowen has upgraded Tempus AI’s stock rating to a Buy and raised the price target to $74, citing the acquisition’s potential to enhance the company’s revenue base and growth prospects. Analysts at TD Cowen noted the favorable impact of the acquisition despite Ambry’s slower growth rate, highlighting opportunities for margin expansion and positive free cash flow.
Additionally, Tempus AI has launched olivia, an AI-enabled health concierge app designed to centralize patient health data and provide actionable insights. This app aggregates health information from over 1,000 systems, offering features like a Smart Profile Summary and AI-enabled Notetaker. The launch of olivia has been met with investor optimism, reflecting confidence in its potential to transform patient engagement and care.
Furthermore, Tempus AI has entered a multi-year agreement with Genialis to validate new RNA-based biomarker algorithms, utilizing Tempus’s multimodal dataset across various cancer types. This collaboration aims to advance the development of predictive biomarkers in cancer treatments. These developments underscore Tempus AI’s commitment to leveraging technology for precision medicine and improved patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.